abstract |
The present disclosure relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg) -depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals. |